BRPI0507182A - uso de compostos organo-silicados para restringir os tecidos conjuntivos lesados - Google Patents

uso de compostos organo-silicados para restringir os tecidos conjuntivos lesados

Info

Publication number
BRPI0507182A
BRPI0507182A BRPI0507182-8A BRPI0507182A BRPI0507182A BR PI0507182 A BRPI0507182 A BR PI0507182A BR PI0507182 A BRPI0507182 A BR PI0507182A BR PI0507182 A BRPI0507182 A BR PI0507182A
Authority
BR
Brazil
Prior art keywords
organo
injured
inhibitor
monomethylsilanetriol
glycoproteins
Prior art date
Application number
BRPI0507182-8A
Other languages
English (en)
Inventor
Marie-Christine Seguin
Yann Courbebaisse
Original Assignee
Exsymol Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exsymol Sa filed Critical Exsymol Sa
Publication of BRPI0507182A publication Critical patent/BRPI0507182A/pt
Publication of BRPI0507182B1 publication Critical patent/BRPI0507182B1/pt
Publication of BRPI0507182B8 publication Critical patent/BRPI0507182B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

USO DE COMPOSTOS ORGANO-SILICADOS PARA RESTRINGIR OS TECIDOS CONJUNTIVOS LESADOS. A presente invenção se refere ao uso de compostos organo-silicados representado pela fórmula geral (I) a seguir: No qual R e x são conforme definidos na descrição, os ditos compostos organo-silicados sendo estabilizados por um composto orgânico portador de uma ou de várias funções álcool, fenol, ácido, amina ou aminoácido, para restringir a organização das fibras protéicas e glicoprotéicas da matriz extracelular dos tecidos conjuntivos lesados.
BRPI0507182A 2004-02-05 2005-02-03 uso de compostos organo-silicados para restringir os tecidos conjuntivos lesados BRPI0507182B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0401095 2004-02-05
FR0401095A FR2865935B1 (fr) 2004-02-05 2004-02-05 Utilisation de composes organo-silicies pour contraindre des tissus conjonctifs leses par l'intermediaire d'une action mecanique
PCT/FR2005/000229 WO2005082421A1 (fr) 2004-02-05 2005-02-03 Utilisation de composes organo-silicies pour contraindre des tissus conjonctifs leses

Publications (3)

Publication Number Publication Date
BRPI0507182A true BRPI0507182A (pt) 2007-06-26
BRPI0507182B1 BRPI0507182B1 (pt) 2019-01-29
BRPI0507182B8 BRPI0507182B8 (pt) 2021-07-27

Family

ID=34778526

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507182A BRPI0507182B8 (pt) 2004-02-05 2005-02-03 uso de compostos organo-silicados para restringir os tecidos conjuntivos lesados

Country Status (11)

Country Link
EP (1) EP1750770B1 (pt)
KR (1) KR101162389B1 (pt)
CN (1) CN1917904B (pt)
AT (1) ATE537846T1 (pt)
BR (1) BRPI0507182B8 (pt)
ES (1) ES2377750T3 (pt)
FR (1) FR2865935B1 (pt)
MX (1) MXPA06008898A (pt)
PL (1) PL1750770T3 (pt)
PT (1) PT1750770E (pt)
WO (1) WO2005082421A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2936708B1 (fr) 2008-10-03 2012-08-17 Exsymol Sa Complexe associant un derive organique du silicium avec des fragments calibres d'acide hyaluronique, a action preventive et reparatrice des degradations cutanees.
FR3094211B1 (fr) * 2019-04-01 2023-11-17 Exsymol Sa utilisation cosmétique de composés organo-siliciés
US20220408756A1 (en) * 2019-06-28 2022-12-29 Rxw Group Nv Poultry feed and drinking water composition comprising monomethylsilanetriol
EP4385486A1 (en) * 2022-12-16 2024-06-19 Laboratoires Fill-Med Manufacturing Combination of an organosilicon compound with a crosslinked glycosaminoglucan for preventing and repairing cutaneous ageing

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR5201M (pt) * 1965-11-05 1967-06-26
FR2158068B1 (pt) * 1971-10-25 1975-02-07 Gueyne Jean
JPS60204708A (ja) * 1984-03-30 1985-10-16 Lion Corp 化粧料用保湿剤
FR2610522B1 (fr) * 1987-02-06 1989-08-18 Gueyne Jean Produit therapeutique a base de derives organiques du silicium
FR2611496B1 (fr) * 1987-03-04 1992-07-03 Gueyne Jean Organo-silicies cosmetiques
JPS6437955A (en) * 1987-08-04 1989-02-08 Kubo Gijutsu Jimusho Kk Deodorant using silicic solution
FR2755968B1 (fr) * 1996-11-19 1998-12-24 Oreal Nouveaux derives silicies de flavones filtres, compositions cosmetiques photoprotectrices les contenant et utilisations
FR2781675B1 (fr) * 1998-07-31 2001-09-07 Berkem Sa Produit bioactif contenant du silicium et des bioflavonoides, ses procedes de preparation et ses utilisations pharmaceutique, dietetique et cosmetique
JP4002760B2 (ja) * 2001-12-21 2007-11-07 株式会社ノエビア 皮膚外用剤

Also Published As

Publication number Publication date
CN1917904A (zh) 2007-02-21
KR20060130620A (ko) 2006-12-19
MXPA06008898A (es) 2007-02-16
CN1917904B (zh) 2012-03-21
FR2865935B1 (fr) 2006-06-23
ES2377750T3 (es) 2012-03-30
ATE537846T1 (de) 2012-01-15
FR2865935A1 (fr) 2005-08-12
KR101162389B1 (ko) 2012-07-04
EP1750770B1 (fr) 2011-12-21
PL1750770T3 (pl) 2012-05-31
WO2005082421A1 (fr) 2005-09-09
BRPI0507182B1 (pt) 2019-01-29
PT1750770E (pt) 2011-12-21
BRPI0507182B8 (pt) 2021-07-27
EP1750770A1 (fr) 2007-02-14

Similar Documents

Publication Publication Date Title
Kim et al. Protective effects of standardized Siegesbeckia glabrescens extract and its active compound kirenol against UVB-induced photoaging through inhibition of MAPK/NF-κB pathways
BR0308196A (pt) Composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições associadas com a glicogênio sintase cinase-3, e de doenças, e, processo para a preparação de um composto
Zhou et al. Protective role of taurine against morphine-induced neurotoxicity in C6 cells via inhibition of oxidative stress
US8975294B2 (en) Desferrioxamine-metal complexes for the treatment of immune-related disorders
AU758264B2 (en) Inorganic nitrite and organic acid in combination as topical antiviral composition
BRPI0411255A (pt) composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto
BRPI0519774A2 (pt) composto ou um sal farmaceuticamente aceitÁvel do mesmo, formulaÇço farmacÊutica, uso de um composto ou um sal farmaceuticamente aceitÁvel do mesmo, mÉtodo de tratamento de uma doenÇa em que inibiÇço da atividade de um membro da famÍlia mapeg É desejada e/ou necessÁria, produto combinado, e, processo para a preparaÇço de um composto
BR0315337A (pt) Composto, formulação farmacêutica, e, método para tratar câncer
US12194019B2 (en) Compositions and methods for treating pain with wogonin
CN111936126A (zh) 用于皮炎和炎症性皮肤病的大麻素给药方案
US20220226280A1 (en) Compositions and methods for increased glucose uptake and fat metabolism
BRPI0510080A (pt) combinações farmacêuticas contendo benzoxazina para tratar doenças respiratórias
DK2196202T3 (da) Lys-Pro-Thr og Lys-Pro som betændelseshæmmende forbindelser
BR112014002885A2 (pt) uso de composto orgânico para o tratamento da síndrome de noonan
AR035750A1 (es) Uso de n- (piridinilamino) indoles para la preparacion de medicamentos para el tratamiento de enfermedades o trastornos desmielinizantes
CA2522146A1 (en) Uptake of macromolecules
BRPI0507182A (pt) uso de compostos organo-silicados para restringir os tecidos conjuntivos lesados
US6174541B1 (en) Skin aging and wound treatment using cell migration agents
WO2017129108A1 (zh) 一种用于治疗皮肤病的硅凝胶
CN103025324A (zh) 用于鼻内施用的具有橄榄提取物（羟基酪醇）和啤酒花提取物（黄腐酚）的药物组合物
BR112012020828B1 (pt) preparado farmacêutico que contém miramistina e seu uso
US20140349957A1 (en) Compositions for Photodynamic Therapy Chemically Modified to Increase Epithelia Penetration and Cellular Bioavailability
MX2014006051A (es) Uso de alcoholes pegilados para el tratamiento de queratosis actinica.
JP2010047535A (ja) 皮膚外用剤
CN1298321C (zh) 光损伤调控物在制备用于抑制由紫外线引起的光损伤的药物中的用途

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 31/737 (2006.01), A61K 31/60 (2006.01), A61K

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/01/2019, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/02/2005, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2865 DE 02-12-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.